+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Sickle Cell Disease"

Hemoglobinopathies - Global Strategic Business Report - Product Thumbnail Image

Hemoglobinopathies - Global Strategic Business Report

  • Report
  • July 2025
  • 192 Pages
  • Global
From
Rare Hematology Market 2024-2028 - Product Thumbnail Image

Rare Hematology Market 2024-2028

  • Report
  • October 2024
  • 210 Pages
  • Global
From
Bleeding Disorders Treatment Market Report 2025 - Product Thumbnail Image

Bleeding Disorders Treatment Market Report 2025

  • Report
  • January 2025
  • 200 Pages
  • Global
From
From
Rare Hematology - Global Strategic Business Report - Product Thumbnail Image

Rare Hematology - Global Strategic Business Report

  • Report
  • July 2025
  • 194 Pages
  • Global
From
From
Hematology Testing Market - Global Outlook & Forecast 2022-2027 - Product Thumbnail Image

Hematology Testing Market - Global Outlook & Forecast 2022-2027

  • Report
  • December 2021
  • 346 Pages
  • Global
From
From
From
From
From
From
Molecular Hematology. Edition No. 5 - Product Thumbnail Image

Molecular Hematology. Edition No. 5

  • Book
  • April 2024
  • 448 Pages
Postgraduate Haematology. Edition No. 7 - Product Thumbnail Image

Postgraduate Haematology. Edition No. 7

  • Book
  • January 2016
  • 952 Pages
Loading Indicator

Sickle Cell Disease (SCD) is a group of inherited red blood cell disorders caused by a genetic mutation in the hemoglobin gene. It is characterized by red blood cells that are shaped like a sickle, or crescent, which can cause blockages in small blood vessels. This can lead to a wide range of symptoms, including anemia, pain, organ damage, and stroke. SCD is most common among people of African, Mediterranean, and Indian descent, and is estimated to affect millions of people worldwide. Treatment for SCD is focused on managing symptoms and preventing complications. This includes medications to reduce pain, antibiotics to prevent infections, and blood transfusions to reduce the risk of stroke. In some cases, stem cell transplants may be used to replace the defective hemoglobin gene. The SCD market is a subset of the larger hematology market, which includes treatments for a variety of blood disorders. Companies in this market include Novartis, GlaxoSmithKline, Pfizer, and Sanofi. Other companies, such as Celgene and Gilead Sciences, are also involved in the development of treatments for SCD. Show Less Read more